Notice of Interim Results

Alliance Pharma PLC
08 August 2006


For Immediate Release                                              8 August 2006


                              ALLIANCE PHARMA PLC
                         ('Alliance' or 'the Company')

                        Notification of Interim Results


On behalf of our client Alliance Pharma plc (AIM: APH), the emerging speciality
pharmaceutical company, we notify that they will be reporting their Interims
Results for the six months ended 30 June, 2006 on Wednesday 13 September, 2006.


For further information:
 Buchanan Communications                        + 44 (0) 20 7466 5000
 Mark Court/ Rebecca Skye Dietrich


Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 32 branded pharmaceutical products and continues to explore
opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to UK and International pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.

Alliance Pharma is also developing Posidorm(R) for sleep disorders and Isprelor
(R) for the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.




                      This information is provided by RNS
            The company news service from the London Stock Exchange